Floatz logo

NADROPARIN

Venous Thromboembolism

Rijnstate Hospitalother_biologicalPhase 4 / ApprovedDormant
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Venous Thromboembolism cohort.

Asset / SponsorPhaseRating
WARFARIN
Northern Jiangsu People's Hospital
Phase 4A
Apixaban
Regeneron Pharmaceuticals
Phase 4BBB
Aspirin
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 4BBB
Rivaroxaban
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3BBB
Dalteparin
Beijing Friendship Hospital
Phase 4BBB

View all 28 →

Same molecule, other indications

NADROPARIN is also rated in:

portal vein thrombosisActive
BB
Indicative · Phase 4
68 / 100
View asset →
iatrogenic diseaseDormant
BB
Indicative · Phase 4
65 / 100
View asset →
cirrhosis of liverDormant
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →